FRANKLIN, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq SC: SONT) announced today that Thomas W. Davison,
President and Chief Executive Officer, is scheduled to present at the Rodman &
Renshaw Techvest 6th Annual Healthcare Conference on Thursday October 28, at
11:30 a.m. ET at the Waldorf Astoria in New York City.
Mr. Davison will provide participants with an update on the Company's
current operations, including the launch of the SonoPrep ultrasonic skin
permeation device and procedure tray with lidocaine, topical vaccine research,
and partnership with Bayer Diagnostics to design a non-invasive 24-hour
glucose-monitoring device for diabetics.
The presentation will be available as a live audio and visual Webcast at
http://www.wallstreetwebcasting.com/webcast/rrshq4/sont. A replay of this
presentation will be available for 90 days at the aforementioned URL.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a leading developer of transdermal drug
delivery and diagnostic products that combine Sontra's SonoPrep ultrasound-
mediated skin permeation technology with synergistic biosensor and transdermal
drug delivery technologies. Sontra is marketing the SonoPrep device and
procedure tray for use with topical lidocaine to achieve rapid (within five
minutes) skin anesthesia. Products under development include: a continuous
non-invasive glucose monitor developed in collaboration with Bayer Diagnostics
and the use of SonoPrep for the transdermal delivery of vaccines, pain drugs
and large protein biopharmaceuticals.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements including with
respect to Sontra's product development and commercialization efforts and
strategies. Such statements are based on our current expectations and are
subject to a number of factors and uncertainties, which could cause actual
results to differ materially from those described in the forward-looking
statements. The following important factors and uncertainties, among others,
could cause actual results to differ materially from those described in these
forward-looking statements: adverse results in product development, clinical
trials, commercialization efforts and market acceptance; difficulties or
delays in obtaining regulatory approvals to market products resulting from
development efforts; difficulties or delays associated with sources of
transdermal drugs; failure to obtain and maintain patent protection for
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; dependence upon strategic partners and third-party distributors
to develop, commercialize, market and sell products based on our work; the
commercial success of products; and the requirement for substantial funding to
conduct research and development and to expand commercialization and marketing
activities. For detailed information about factors that could cause actual
results to differ materially from those described in the forward-looking
statements, please refer to Sontra's filings with the Securities and Exchange
Commission, including Sontra's most recent Quarterly Report on Form 10-QSB.
Forward-looking statements represent management's current expectations and are
inherently uncertain. We do not undertake any obligation to update forward-
looking statements made by us.
Contacts:
Sean Moran, CFO
Sontra Medical Corporation
Tel: 508-553-8850
Evan Smith, CFA / Erica Pettit
KCSA Worldwide
Tel: 212-896-1251 / 212-896-1248
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran, CFO of Sontra Medical
Corporation, +1-508-553-8850; or Evan Smith, CFA,
+1-212-896-1251, or Erica Pettit, +1-212-896-1248, both of KCSA
Worldwide
|
